Redeye comments on ADVANCE II’s principal investigator presenting an ADVANCE II survival update at ASH 2023. We believe the trial’s median progression-free survival of c30.4 months underlines vididencel’s potential to meaningfully improve AML maintenance therapy. We judge the survival update bodes well for the company’s coming phase II CADENCE trial. Further, survival data aligned with our expectations based on previous readouts.